Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Publication year range
1.
Small ; 19(34): e2301606, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37086133

ABSTRACT

Potassium-ion batteries (PIBs) have attracted more and more attention as viable alternatives to lithium-ion batteries (LIBs) due to the deficiency and uneven distribution of lithium resources. However, it is shown that potassium storage in some compounds through reaction or intercalation mechanisms cannot effectively improve the capacity and stability of anodes for PIBs. The unique anti-spinel structure of magnetite (Fe3 O4 ) is densely packed with thirty-two O atoms to form a face-centered cubic (fcc) unit cell with tetrahedral/octahedral vacancies in the O-closed packing structure, which can serve as K+ storage sites according to the density functional theory (DFT) calculation results. In this work, carbon-coated Fe3 O4 @C nanoparticles are prepared as high-performance anodes for PIBs, which exhibit high reversible capacity (638 mAh g-1 at 0.05 A g-1 ) and hyper stable cycling performance at ultrahigh current density (150 mAh g-1 after 9000 cycles at 10 A g-1 ). In situ XRD, ex-situ Fe K-edge XAFS, and DFT calculations confirm the storage of K+ in tetrahedral/octahedral vacancies.

2.
BMC Pediatr ; 22(1): 615, 2022 10 26.
Article in English | MEDLINE | ID: mdl-36289457

ABSTRACT

BACKGROUND: Childhood asthma has substantial effects on children's health. It is important to identify factors in early life that influence childhood asthma. Accumulating evidence indicates that Helicobacter pylori may protect against allergic diseases. This study aimed to evaluate the relationship between H. pylori infection and pediatric asthma in Chongqing, China. MATERIALS AND METHODS: This cross-sectional study included healthy children aged 4-18 years who underwent a 13C urea breath test during medical checkups in 2021. All medical information was extracted from electronic medical records and a big data system. Logistic regression was used to evaluate the association between H. pylori infection and pediatric asthma, and multivariate regression models were adjusted for covariates. RESULTS: In our study, 2241 participants, including 1240 boys (55.33%) and 1001 girls (44.67%), underwent urea breath testing (average age: 8.67 ± 2.70 years). Among them, 292 (13.03%) were positive for H. pylori and 152 (6.78%) had asthma. The rates of asthma diagnosis in H. pylori-negative and -positive children were 7.23% and 3.77%, respectively (odds ratio = 1.995; 95% confidence interval: 1.003-3.968; P < .05). Furthermore, family history of asthma and the percentage of eosinophils in routine blood examination were associated with childhood asthma; however, the body mass index, platelet count, and serum vitamin D level were not. CONCLUSIONS: We demonstrated a significant inverse association between H. pylori infection and pediatric asthma in Chongqing, China. Further studies are required to determine the causal association and underlying mechanisms to prevent and control childhood asthma.


Subject(s)
Asthma , Helicobacter Infections , Helicobacter pylori , Male , Female , Child , Humans , Child, Preschool , Helicobacter Infections/complications , Helicobacter Infections/diagnosis , Helicobacter Infections/epidemiology , Cross-Sectional Studies , Prevalence , Breath Tests , Asthma/diagnosis , Asthma/epidemiology , Asthma/etiology , China/epidemiology , Urea , Body Mass Index , Vitamin D
3.
ACS Appl Mater Interfaces ; 13(45): 54308-54314, 2021 Nov 17.
Article in English | MEDLINE | ID: mdl-34727693

ABSTRACT

Potassium ion batteries (KIBs) have attracted great attention recently as a promising large-scale energy storage system by virtue of the bountiful K resource and low standard hydrogen potential of K+/K. However, their development is hindered by the limited capacity and inferior cycling stability resulting from the large size of K+. Here, a unique vanadium sulfide@carbon nanorod is designed and synthesized for high-performance KIBs. Thanks to the hybrid structure, abundant active sites, fast ion diffusion, and capacitive-like electrochemical behavior of the electrode, the anode exhibits a large specific capacity (468 mA h g-1 after 100 cycles at 0.1 A g-1), predominant rate performance (205 mA h g-1 at 5 A g-1), and impressive cycling stability (171 mA h g-1 for 4000 cycles at 3 A g-1). Furthermore, the constructed KIB full cell demonstrates 229 mA h g-1 at 0.5 A g-1 and 86% capacity retention over 300 cycles.

4.
ACS Appl Mater Interfaces ; 13(44): 52697-52705, 2021 Nov 10.
Article in English | MEDLINE | ID: mdl-34704731

ABSTRACT

Metal phosphides with a high theoretical capacity and low redox potential have been proposed as promising anodes for potassium-ion batteries (PIBs). A reasonable configuration design and introduction of a hollow structure with adequate internal void spaces are effective strategies to overcome the volume expansion of metal phosphides in potassium-ion batteries. Herein, we report a cage-confinement pyrolysis strategy to obtain hollow nanocage-structured nitrogen/phosphorus dual-doped carbon-coated copper phosphide (Cu3P/CuP2@NPC), which exhibits a high initial charge capacity (409 mA h g-1 at 100 mA g-1) and an outstanding cycle performance (100 mA h g-1 after 5000 cycles at 1000 mA g-1) as an anode material for PIBs. The novel hollow nanocage structure could prevent volume expansion during cycling and reduce the electron/ion diffusion distance. Besides, the nitrogen/phosphorus dual-doped carbon-coated layer could promote electronic conductivity. In situ X-ray diffraction (XRD) measurements are conducted to study the potassiation/depotassiation mechanism of Cu3P/CuP2@NPC and reveal the structure stability during the cycle process, which further proves that the design ideas of the conductive carbon layer and the hollow structure with adequate internal void spaces are successful.

5.
ACS Appl Mater Interfaces ; 13(29): 33926-33936, 2021 Jul 28.
Article in English | MEDLINE | ID: mdl-34254767

ABSTRACT

Artemisinin compounds have shown satisfactory safety records in anti-malarial clinical practice over decades and have revealed value as inexpensive anti-tumor adjuvant chemotherapeutic drugs. However, the rational design and precise preparation of nanomedicines based on the artemisinin drugs are still limited due to their non-aromatic and fragile chemical structure. Herein, a bioinspired coordination-driven self-assembly strategy was developed to manufacture the artemisinin-based nanoprodrug with a significantly increased drug loading efficacy (∼70 wt %) and decreased preparation complexity compared to conventional nanodrugs. The nanoprodrug has suitable size distribution and robust colloidal stability for cancer targeting in vivo. The nanoprodrug was able to quickly disassemble in the tumor microenvironment with weak acidity and a high glutathione concentration, which guarantees a better tumor inhibitory effect than direct administration and fewer side effects on normal tissues in vivo. This work highlights a new strategy to harness a robust, simplified, organic solvent-free, and highly repeatable route for nanoprodrug manufacturing, which may offer opportunities to develop cost-effective, safe, and clinically available nanomedicines.


Subject(s)
Antineoplastic Agents/therapeutic use , Artesunate/therapeutic use , Drug Carriers/therapeutic use , Nanoparticles/therapeutic use , Neoplasms/drug therapy , Prodrugs/therapeutic use , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/toxicity , Artesunate/chemistry , Artesunate/pharmacokinetics , Artesunate/toxicity , Cell Line, Tumor , Drug Carriers/chemistry , Drug Carriers/pharmacokinetics , Drug Carriers/toxicity , Hemolysis/drug effects , Histidine/chemistry , Histidine/pharmacokinetics , Histidine/therapeutic use , Histidine/toxicity , Humans , Mice, Inbred BALB C , Nanoparticles/chemistry , Nanoparticles/toxicity , Prodrugs/chemistry , Prodrugs/pharmacokinetics , Prodrugs/toxicity , Proof of Concept Study
6.
Zhongguo Dang Dai Er Ke Za Zhi ; 21(4): 393-398, 2019 Apr.
Article in Chinese | MEDLINE | ID: mdl-31014435

ABSTRACT

OBJECTIVE: To study the clinical effect of different combinations of fluticasone propionate (Flu), montelukast sodium (Mon) and ketotifen (Ket) in the treatment of children with cough variant asthma (CVA). METHODS: A total of 280 children with CVA who were admitted to the department of respiratory medicine from June 2015 to January 2018 were randomly divided into Flu+Mon+Ket, Flu+Mon, Flu+Ket, Mon+Ket, Flu, Mon and Ket groups, with 40 children in each group. The children in each group were given corresponding drug(s), and the course of treatment was 3 months for all groups. The condition of cough, cough symptom score, pulmonary function and adverse drug reactions were evaluated after 2 and 3 months of treatment. The children were followed up to observe recurrence. RESULTS: After treatment, cough symptom score tended to decrease in all 7 groups, with increases in percentage of forced expiratory volume in 1 second (FEV1%) and percentage of predicted peak expiratory flow (PEF%). After 2 months of treatment, the Flu+Mon+Ket group had a significantly lower cough symptom score and significantly higher FEV1% and PEF% than the other groups (P<0.05). After 2 and 3 months of treatment, the Ket group had a significantly higher cough symptom score and significantly lower FEV1% and PEF% than the other groups (P<0.05). After 3 months of treatment, there were no significant differences in cough symptom score, FEV1% and PEF% among the other groups (P>0.05). There was a low incidence rate of adverse events in all 7 groups, and there was no significant difference among the 7 groups (P>0.05). The Ket group had a significantly higher recurrence rate of cough than the other groups (P<0.001), while there was no significant difference in this rate among the other groups (P>0.0024). CONCLUSIONS: For children with CVA, a combination of Flu, Mon and Ket has a better clinical effect than a combination of two drugs and a single drug at 2 months of treatment and is safe. After 3 months of treatment, Flu or Mon alone has a similar effect to drug combination. Ket alone has a poor clinical effect and a high recurrence rate after drug withdrawal.


Subject(s)
Asthma , Cough/drug therapy , Acetates , Androstadienes , Anti-Asthmatic Agents , Asthma/drug therapy , Child , Cyclopropanes , Drug Combinations , Fluticasone , Humans , Ketotifen , Quinolines , Sulfides
SELECTION OF CITATIONS
SEARCH DETAIL
...